JP2009515949A - 新規な２−アミノピリミジノン誘導体およびそれらの使用 - Google Patents
新規な２−アミノピリミジノン誘導体およびそれらの使用 Download PDFInfo
- Publication number
- JP2009515949A JP2009515949A JP2008541107A JP2008541107A JP2009515949A JP 2009515949 A JP2009515949 A JP 2009515949A JP 2008541107 A JP2008541107 A JP 2008541107A JP 2008541107 A JP2008541107 A JP 2008541107A JP 2009515949 A JP2009515949 A JP 2009515949A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- arylalkyl
- heteroarylalkyl
- aryl
- cycloalkylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 155
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 79
- 206010012289 Dementia Diseases 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 26
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 831
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 671
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 655
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 628
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 606
- 125000003118 aryl group Chemical group 0.000 claims description 597
- 125000001072 heteroaryl group Chemical group 0.000 claims description 566
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 557
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 531
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 422
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 408
- 125000005843 halogen group Chemical group 0.000 claims description 345
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 286
- 125000003545 alkoxy group Chemical group 0.000 claims description 191
- 229910052799 carbon Inorganic materials 0.000 claims description 153
- 229910052739 hydrogen Inorganic materials 0.000 claims description 138
- 229910052717 sulfur Inorganic materials 0.000 claims description 137
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 105
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 104
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 81
- 125000000304 alkynyl group Chemical group 0.000 claims description 78
- 125000001424 substituent group Chemical group 0.000 claims description 73
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 71
- 125000003282 alkyl amino group Chemical group 0.000 claims description 68
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 66
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 52
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 48
- 239000002243 precursor Substances 0.000 claims description 35
- 238000001727 in vivo Methods 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 238000006467 substitution reaction Methods 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 206010059245 Angiopathy Diseases 0.000 claims description 17
- 201000010374 Down Syndrome Diseases 0.000 claims description 17
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 15
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 14
- 208000018737 Parkinson disease Diseases 0.000 claims description 14
- 230000003412 degenerative effect Effects 0.000 claims description 14
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 14
- 230000002792 vascular Effects 0.000 claims description 14
- 208000000044 Amnesia Diseases 0.000 claims description 13
- 230000006735 deficit Effects 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 13
- 208000028698 Cognitive impairment Diseases 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 12
- 206010036631 Presenile dementia Diseases 0.000 claims description 12
- 208000026139 Memory disease Diseases 0.000 claims description 11
- 230000006984 memory degeneration Effects 0.000 claims description 11
- 208000023060 memory loss Diseases 0.000 claims description 11
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 11
- 206010044688 Trisomy 21 Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 9
- 230000007850 degeneration Effects 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 7
- 206010039966 Senile dementia Diseases 0.000 claims description 7
- 210000004227 basal ganglia Anatomy 0.000 claims description 7
- 230000001054 cortical effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000007170 pathology Effects 0.000 claims description 6
- 102100021257 Beta-secretase 1 Human genes 0.000 claims description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000002664 nootropic agent Substances 0.000 claims description 3
- PFWVTHUDSZRCTO-UHFFFAOYSA-N 2-amino-1-methyl-5-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1N=C(N)N(C)C=C1CCC1=CC=CC=C1 PFWVTHUDSZRCTO-UHFFFAOYSA-N 0.000 claims description 2
- QRZKQTGJCKDSGN-UHFFFAOYSA-N 2-amino-3,5-dimethyl-6-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC=C1 QRZKQTGJCKDSGN-UHFFFAOYSA-N 0.000 claims description 2
- UMPOTDYQEMLZRZ-UHFFFAOYSA-N 2-amino-3-methyl-5-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1N(C)C(N)=NC=C1CCC1=CC=CC=C1 UMPOTDYQEMLZRZ-UHFFFAOYSA-N 0.000 claims description 2
- NTOOSRIQBIMWSJ-UHFFFAOYSA-N 2-amino-3-methyl-5-phenyl-6-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1C=1C(=O)N(C)C(N)=NC=1CCC1=CC=CC=C1 NTOOSRIQBIMWSJ-UHFFFAOYSA-N 0.000 claims description 2
- MALAKURYZJFBLT-UHFFFAOYSA-N 2-amino-3-methyl-6-(2-phenylethyl)pyrimidin-4-one Chemical compound O=C1N(C)C(N)=NC(CCC=2C=CC=CC=2)=C1 MALAKURYZJFBLT-UHFFFAOYSA-N 0.000 claims description 2
- NEKSSFOSVQFARB-UHFFFAOYSA-N 2-amino-4-(3-bromo-4-chlorophenyl)-4,5-dimethyl-1,5-dihydropyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1C(=O)NC(N)=NC1(C)C1=CC=C(Cl)C(Br)=C1 NEKSSFOSVQFARB-UHFFFAOYSA-N 0.000 claims description 2
- GZPIUMLCUOIOIU-UHFFFAOYSA-N 2-amino-5-(2-phenylethyl)-1h-pyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1NC(N)=NC=C1CCC1=CC=CC=C1 GZPIUMLCUOIOIU-UHFFFAOYSA-N 0.000 claims description 2
- XMKDVXUWXNFCOG-UHFFFAOYSA-N 2-amino-5-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-1h-pyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC=3C(NC(N)=NC=3)=O)C=CC=2)=C1 XMKDVXUWXNFCOG-UHFFFAOYSA-N 0.000 claims description 2
- PLXBBXSHAWKMPQ-UHFFFAOYSA-N 2-amino-5-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC=3C(N(C)C(N)=NC=3)=O)C=CC=2)=C1 PLXBBXSHAWKMPQ-UHFFFAOYSA-N 0.000 claims description 2
- UJZKVDNGADIRTE-UHFFFAOYSA-N 2-amino-5-benzyl-6-[2-(3-bromophenyl)ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CC=1C(=O)N(C)C(N)=NC=1CCC1=CC=CC(Br)=C1 UJZKVDNGADIRTE-UHFFFAOYSA-N 0.000 claims description 2
- HUUIHHSBUQUGQT-UHFFFAOYSA-N 2-amino-5-benzyl-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3=C(C(=O)N(C)C(N)=N3)CC=3C=CC=CC=3)C=CC=2)=C1 HUUIHHSBUQUGQT-UHFFFAOYSA-N 0.000 claims description 2
- BVQRDQHLQSWFKK-UHFFFAOYSA-N 2-amino-5-bromo-3-methyl-6-(2-phenylethyl)pyrimidin-4-one Chemical compound O=C1N(C)C(N)=NC(CCC=2C=CC=CC=2)=C1Br BVQRDQHLQSWFKK-UHFFFAOYSA-N 0.000 claims description 2
- CNBSPUGFNQVSJS-UHFFFAOYSA-N 2-amino-6-(2-phenylethyl)-1h-pyrimidin-4-one Chemical compound N1C(N)=NC(=O)C=C1CCC1=CC=CC=C1 CNBSPUGFNQVSJS-UHFFFAOYSA-N 0.000 claims description 2
- BSFYBPPWNXZIPH-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-1h-pyrimidin-4-one Chemical compound O=C1NC(N)=NC(CCC=2C=C(Br)C=CC=2)=C1 BSFYBPPWNXZIPH-UHFFFAOYSA-N 0.000 claims description 2
- MUWOCUNRCCSVTE-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-5-methyl-1h-pyrimidin-4-one Chemical compound N1=C(N)NC(=O)C(C)=C1CCC1=CC=CC(Br)=C1 MUWOCUNRCCSVTE-UHFFFAOYSA-N 0.000 claims description 2
- DTBQCGNZLPFKJS-UHFFFAOYSA-N 2-amino-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3,5-dimethylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3=C(C(=O)N(C)C(N)=N3)C)C=CC=2)=C1 DTBQCGNZLPFKJS-UHFFFAOYSA-N 0.000 claims description 2
- SXFTZSKTVNASQO-UHFFFAOYSA-N 2-amino-6-[2-[3-(furan-2-yl)phenyl]ethyl]-3,5-dimethylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC(C=2OC=CC=2)=C1 SXFTZSKTVNASQO-UHFFFAOYSA-N 0.000 claims description 2
- VDDYOHIPPWWPQC-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-3,8-dimethyl-6,7-dihydro-5h-quinazolin-4-one Chemical compound O=C1N(C)C(N)=NC2=C1CCCC2(C)CC1=CC=CC(Br)=C1 VDDYOHIPPWWPQC-UHFFFAOYSA-N 0.000 claims description 2
- NXTSOXXYMHVMIN-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-3-methyl-5,6,7,8-tetrahydroquinazolin-4-one Chemical compound C1CCC=2C(=O)N(C)C(N)=NC=2C1CC1=CC=CC(Br)=C1 NXTSOXXYMHVMIN-UHFFFAOYSA-N 0.000 claims description 2
- YAVQQCQABYEAMN-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-5,6,7,8-tetrahydro-1h-quinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=2NC(N)=NC(=O)C=2CCCC1CC1=CC=CC(Br)=C1 YAVQQCQABYEAMN-UHFFFAOYSA-N 0.000 claims description 2
- XKOANOLURVHUGM-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-8-methyl-1,5,6,7-tetrahydroquinazolin-4-one Chemical compound C1CCC(C(NC(N)=N2)=O)=C2C1(C)CC1=CC=CC(Br)=C1 XKOANOLURVHUGM-UHFFFAOYSA-N 0.000 claims description 2
- QDUPIWKQAWTULW-UHFFFAOYSA-N 2-amino-8-[[3-(3-methoxyphenyl)phenyl]methyl]-3,8-dimethyl-6,7-dihydro-5h-quinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CC3(C)C4=C(C(N(C)C(N)=N4)=O)CCC3)C=CC=2)=C1 QDUPIWKQAWTULW-UHFFFAOYSA-N 0.000 claims description 2
- OPBNBRSINBFTFT-UHFFFAOYSA-N 2-amino-8-[[3-(3-methoxyphenyl)phenyl]methyl]-3-methyl-5,6,7,8-tetrahydroquinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CC3C4=C(C(N(C)C(N)=N4)=O)CCC3)C=CC=2)=C1 OPBNBRSINBFTFT-UHFFFAOYSA-N 0.000 claims description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 239000003695 memory enhancer Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- QZJVGUKULLSSCO-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-3,5-dimethylpyrimidin-4-one Chemical compound N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC(Br)=C1 QZJVGUKULLSSCO-UHFFFAOYSA-N 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- -1 Arirua Kill Chemical group 0.000 description 16
- 125000001188 haloalkyl group Chemical group 0.000 description 10
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 7
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004965 chloroalkyl group Chemical group 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 101710150192 Beta-secretase 1 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010048327 Supranuclear palsy Diseases 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000037411 cognitive enhancing Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 231100000863 loss of memory Toxicity 0.000 description 2
- 230000006883 memory enhancing effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- SNYJCMSGXKYXCK-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-3,5-dimethylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC(Br)=C1 SNYJCMSGXKYXCK-UHFFFAOYSA-N 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 101150049278 US20 gene Proteins 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 229940068796 clozaril Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 125000005215 cycloalkylheteroaryl group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- 229940003380 geodon Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940034173 symbyax Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 229940039925 zyprexa Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73732605P | 2005-11-15 | 2005-11-15 | |
| PCT/SE2006/001280 WO2007058580A1 (en) | 2005-11-15 | 2006-11-13 | Novel 2-aminopyrimidinone derivatives and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515949A true JP2009515949A (ja) | 2009-04-16 |
| JP2009515949A5 JP2009515949A5 (enExample) | 2010-01-07 |
Family
ID=38048893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541107A Pending JP2009515949A (ja) | 2005-11-15 | 2006-11-13 | 新規な２−アミノピリミジノン誘導体およびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090215801A9 (enExample) |
| EP (1) | EP1951680A4 (enExample) |
| JP (1) | JP2009515949A (enExample) |
| CN (1) | CN101360720A (enExample) |
| WO (1) | WO2007058580A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| WO2006138264A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| ES2537898T3 (es) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| GEP20135793B (en) | 2008-09-11 | 2013-03-25 | Pfizer | Heteroaryls amide derivatives and their use as glucokinase activators |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| JP2012515760A (ja) | 2009-01-20 | 2012-07-12 | ファイザー・インク | 置換ピラジノンアミド |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| JP6274723B2 (ja) | 2009-10-16 | 2018-02-07 | メリンタ セラピューティクス，インコーポレイテッド | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
| JP2013508299A (ja) | 2009-10-16 | 2013-03-07 | リブ−エックス ファーマシューティカルズ，インコーポレイテッド | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
| RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2694521B1 (en) | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| RU2014111055A (ru) | 2011-08-22 | 2015-09-27 | Мерк Шарп И Доум Корп. | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение |
| EP2773207B1 (en) | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| US9937183B2 (en) | 2013-09-09 | 2018-04-10 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| MX2016002975A (es) | 2013-09-09 | 2016-10-21 | Melinta Therapeutics Inc | Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos. |
| WO2016145417A1 (en) | 2015-03-11 | 2016-09-15 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| US11098047B2 (en) | 2016-05-06 | 2021-08-24 | BioVersys AG | Antimicrobials and methods of making and using same |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4625026A (en) * | 1982-12-30 | 1986-11-25 | Biomeasure, Inc. | 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections |
| EP0905136A1 (en) * | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
| AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| YU63802A (sh) * | 2000-02-25 | 2005-06-10 | F. Hoffmann-La Roche Ag. | Modulatori adenozinskih receptora |
| US20030114445A1 (en) * | 2001-06-15 | 2003-06-19 | Chengxin Zhi | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections |
| US6777420B2 (en) * | 2001-06-15 | 2004-08-17 | Microbiotix, Inc. | Heterocyclic antibacterial compounds |
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| US7592348B2 (en) * | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2548388A1 (en) * | 2003-12-15 | 2005-06-30 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2609562A1 (en) * | 2005-06-14 | 2006-12-28 | Schering Corporation | Macrocyclic heterocyclic aspartyl protease inhibitors |
| US7759353B2 (en) * | 2005-06-14 | 2010-07-20 | Schering Corporation | Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment |
| CN101296926A (zh) * | 2005-10-27 | 2008-10-29 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
| CN101351460A (zh) * | 2005-10-31 | 2009-01-21 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
-
2006
- 2006-11-13 WO PCT/SE2006/001280 patent/WO2007058580A1/en not_active Ceased
- 2006-11-13 JP JP2008541107A patent/JP2009515949A/ja active Pending
- 2006-11-13 CN CNA200680051085XA patent/CN101360720A/zh active Pending
- 2006-11-13 EP EP06813003A patent/EP1951680A4/en not_active Withdrawn
- 2006-11-13 US US12/093,670 patent/US20090215801A9/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101360720A (zh) | 2009-02-04 |
| US20080255164A1 (en) | 2008-10-16 |
| WO2007058580A1 (en) | 2007-05-24 |
| EP1951680A4 (en) | 2011-08-10 |
| EP1951680A1 (en) | 2008-08-06 |
| US20090215801A9 (en) | 2009-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090215801A9 (en) | Novel 2-Aminopyrimidinone Derivatives And Their Use | |
| JP2009520685A (ja) | 化合物およびそれらの使用ｉｖ | |
| US7855213B2 (en) | Compounds | |
| JP2008516945A (ja) | 置換されたアミノ化合物およびそれらの使用 | |
| JP2008516946A (ja) | 置換されたアミノ−ピリミドンおよびそれらの使用 | |
| US20090023762A1 (en) | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | |
| CN101360716A (zh) | 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途 | |
| CN101460480A (zh) | 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 | |
| JP2008523139A (ja) | 置換アミノピリジン類及びその使用 | |
| JP2009515951A (ja) | 新規な２−アミノピリミジノンまたは２−アミノピリジノン誘導体およびそれらの使用 | |
| JP2009515950A (ja) | 新規な２−アミノピリミジン誘導体およびその使用 | |
| HK1127035A (en) | Novel 2-aminopyrimidinone derivatives and their use | |
| HK1127036A (en) | Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use | |
| HK1127034A (en) | Novel 2-aminopyrimidine derivatives and their use | |
| HK1127038A (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121204 |